Background. Few trials of treatment for Helicobacter pylori infection have been conducted in high-prevalence or pediatric populations, and risk factors for treatment failure are poorly understood.
The North American Society for Pediatric Gastroenterology and Nutrition recommends use of 2 antibiotics and a proton-pump inhibitor for 10-14 days to treat Helicobacter pylori infection, although these guidelines acknowledge the lack of well-controlled pediatric treatment studies [1] . Available studies are usually small, do not include a placebo arm, are conducted at a single center, involve relatively short follow-up periods, and are conducted primarily among populations in developed countries [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Treatment response and risk factors for treatment failure may differ in developing countries, where most of the world's children reside.
The epidemiologic characteristics of H. pylori in Alaska has certain characteristics found in developing countries, including high prevalence and young age of infection onset [17] . From December 2002 through March 2004, we conducted a study with the primary purpose of evaluating the effect of H. pylori eradication therapy on iron deficiency in children living in rural villages of western Alaska. We present the results of a secondary analysis conducted to determine treatment response and risk factors for treatment failure.
SUBJECTS AND METHODS
Study design and population. We conducted a prospective, household-randomized, open-label treatment trial in 10 western Alaska villages. Randomization was stratified to allow for an equal number of intervention and control households per village. All children 7-11 years of age were eligible to participate. We screened 690 children (69% of the 7-11-year-old population of the study villages) to identify those with iron deficiency and H. pylori infection, all of whom were eligible for the treatment phase of the study.
Study villages had populations of 471-1014 persons, all of whom were predominantly Alaska Natives. None of the villages were accessible by road, 3 did not have public water or sewage systems connected to individual residences, and health care at all villages was delivered by village health aides.
Treatment. Children enrolled in the treatment phase were randomly assigned, by household, to a control group receiving iron sulfate alone (3 mg/kg twice per day, up to 60 mg per dose for 6 weeks) or to an intervention group receiving iron sulfate plus a 2-week course of H. pylori eradication therapy (amoxicillin 40 mg/kg per dose twice per day, up to 1.5 g per dose; clarithromycin 7.5 mg/kg per dose twice per day, up to 500 mg per dose; and lansoprazole 30 mg twice per day) [1, 18, 19] . Children with amoxicillin or macrolide allergy had these drugs replaced by metronidazole therapy (10 mg/kg per dose twice per day, up to 500 mg per dose). Two months after treatment initiation, children were reevaluated for H. pylori infection. Children in the intervention group who were still infected received an additional 2-week course of H. pylori eradication therapy with metronidazole, amoxicillin, and lansoprazole (all of which were administered at the previously described dosages) and bismuth subsalicylate (2 tablets or 2 tablespoons of liquid formulation twice per day). Children with allergy to amoxicillin received clarithromycin in its place.
During both treatment phases, parents or guardians completed daily treatment logs for children in the study. Additionally, we employed village assistants to monitor treatment compliance by direct observation or by telephone conversation and to record results (as well as adverse effects of treatment) on a daily log. During re-treatment, we also performed telephone calls to patients daily from Anchorage, and we placed an additional field worker in the 2 most populous villages whose sole responsibility was to directly observe therapy. For analysis, village assistant logs were used unless data were missing, in which case parent or guardian logs were used.
Definitions and follow-up. Children were considered to be enrolled if they took at least 1 dose of assigned medication. Enrolled children were assessed at initial screening and at ∼2 and ∼8 months after treatment initiation. H. pylori infection was determined using a 13 C urea breath test (Meretek), which has excellent performance among pediatric populations [20, 21] and adult Alaska Native populations [22] . H. pylori infection was defined as a calculated urea hydrolysis rate of 110 from the suggested delta over baseline for 13 CO 2 cutoff of 2.4 after adjusting for weight, height, and sex based on the manufacturer's recommendation for pediatric patients. We defined iron deficiency as a serum ferritin level of !22.5 pmol/L (10 mg/L) using a radioimmunometric assay (ICN Pharmaceuticals Diagnostic Division).
At the initial screening, we administered a nonvalidated questionnaire to assess demographic characteristics, abdominal symptoms, source of water, and water storage. In households without piped water, families collected water from various sources and stored it indoors in containers. We measured height and weight using scales available at village clinics. Medical records were reviewed to determine whether participants had been prescribed antibiotics within 30 days before each followup visit. To our knowledge, none of the subjects had received a diagnosis of H. pylori-related disease immediately before or during the study, and none received proton-pump inhibitors except during the study.
Analysis and sample size calculation. The sample size was determined in the primary study and not in the current subanalysis. Children from 455 households were screened, and 181 households (1-3 children per household) were randomized to receive study treatment. Although treatment assignment was by household, we did not adjust for household during analysis for 2 reasons: the large number of households relative to the number of analyzed individuals would have resulted in overfit models, and the large number of households and the small number of individuals per household suggested that the effect of household randomization was minimal. Because randomization was balanced on a per village basis and to account for potential confounding, multivariate models were adjusted for village of residence.
Analyses were performed with SPSS, version 11.0 (SPSS). Means were compared using a 2-sided independent samples t test. Multiple logistic regression was used to identify variables associated with treatment failure among children in the intervention group after the first round of therapy. We did not formally assess variables associated with treatment failure after the second round of therapy, because all but 8 children had resolved their infection. Because we defined enrollment as receipt of at least 1 dose of medication, results of the per-protocol analysis and the modified intention-to-treat analysis were almost identical (during initial treatment, 1 child in the intervention group received iron but no H. pylori therapy).
Ethical issues. Iron deficiency is not currently a recognized indication for H. pylori therapy. Recent studies, however, have documented an association between iron deficiency and H. pylori infection [22, 23] . Alaska Native children have repeatedly been shown to have very high iron deficiency prevalences de- spite appropriate dietary iron intake [24, 25] . Under these circumstances, the primary purpose of the current study was to determine whether resolution of H. pylori infection would improve iron deficiency.
We obtained approval from the institutional review boards of the US Centers for Disease Control and Prevention and the Alaska Area Health Research Board, from the Human Subjects Committee of the Yukon-Kuskokwim Regional Health Corporation, and from the village or tribal councils of the 10 study villages. Children gave written assent for participation, and their parents or guardians gave written informed consent.
RESULTS

Screening.
Of 690 children screened for study eligibility (figure 1), 335 (49%) were female, and 52 (7.5%) had abdominal pain. A total of 102 (15%) of 683 children for whom screening results were available had a hemoglobin level of !115 g/L, and 576 (99%) of 579 children for whom race was reported on the questionnaire were Alaska Native. Of 666 children with valid urea breath test results and results of ferritin evaluation, 580 (87%) had H. pylori infection, and 258 (39%) had a serum ferritin level of !22.5 pmol/L; 237 (36%) of these 666 children had both conditions and were eligible for the treatment phase.
No association was noted between H. pylori infection and abdominal symptoms (
). P p .5 Of the 237 children eligible for the treatment phase, 118 were assigned to the control group, and 119 were assigned to the intervention group. Five children in the control group and 13 in the intervention group withdrew from the study before taking any medication, leaving 219 children (113 in the control group and 106 in the intervention group) who agreed to participate (figure 1). Of the 106 children assigned to the intervention group, 98 (92%) received standard therapy, 7 (7%) received metronidazole in place of amoxicillin because of amoxicillin allergy, and 1 (1%) received metronidazole in place of clarithromycin because of macrolide allergy.
Treatment response. Of the 219 children enrolled in the treatment phase, 215 were evaluated at 2 months after therapy initiation. Of these 215 children, 35 (34%) of 104 in the intervention group and 1 (0.90%) of 111 in the control group were H. pylori negative (risk ratio, 37; 95% CI, 5.2-268). Within villages, the number of children in the intervention group varied from 3 to 20, and the rate of treatment failure varied from 14% to 100% (7 of 10 villages had a failure rate of 160%).
Sixty-nine of 104 intervention children remained H. pyloriinfected at the 2-month follow-up visit and were offered retreatment. Of these 69 children, 12 refused re-treatment or had moved, whereas 57 received at least 1 re-treatment dose. Among these 57 children, 50 presented for evaluation at the 8-month follow-up visit, and 8 (16%) remained infected with H. pylori. Thirty-five of the 104 children in the intervention group tested negative at the 2-month follow-up visit, of whom 6 (17%) had become reinfected by the 8-month follow-up visit.
We did not document whether all assigned medications were taken at any particular dosing time. However, we recorded the number of scheduled dosing times during which at least some medicine was taken. A total of 8.3% of children who took medicine at !10 of the scheduled times resolved their infection, compared with 19%, 40%, and 63% of those who took medicine at 10-20, 20-27, and all 28 of the scheduled times, respectively ( , by the x 2 test for trend) (table 1). At 8 P ! .001 months, the proportion of the 50 re-treated children who were NOTE. The standard regimen included amoxicillin, clarithromycin, and lansoprazole; metronidazole was replaced by amoxicillin for 7 children allergic to penicillin and by clarithromycin for 1 child allergic to macrolides.
a Includes children from the intervention group who were H. pylori positive at the 2-month follow-up visit and who accepted repeat quadruple therapy (amoxicillin, metronidazole, lansoprazole, and bismuth subsalicylate; clarithromycin was replaced by amoxicillin for children allergic to penicillin). Children in the control group did not receive any therapy. Of 57 re-treated children in the intervention group, 50 were available for testing at 8 months.
cured ranged from 79% to 100% regardless of the number of times medicine was taken. Univariate analysis of risk factors for treatment failure. Among children in the intervention group at 2 months, variables associated with treatment failure at a P value of !.10 included a treatment regimen that did not include metronidazole, male sex, initial serum ferritin level, hemoglobin levels at 2 months, treatment doses, and lower body mass index (tables 2 and 3). Three of 4 household-crowding measures also were associated with treatment failure, including total number of household members, total number of household members aged 7-11 years, and the presence of other household members aged 7-11 years with infection detected during initial screening (table 3) . Treatment response varied by village, but we did not identify village characteristics (such as size or intensity of treatment monitoring) that predicted treatment failure.
Household crowding was examined in greater detail. Among children in the intervention group, the mean and median number of residents per household was 7.0 (range, 2-13 residents).
Of children living in households with у9 residents, 7-8 residents, or !7 residents, 96% (23 of 24 children), 71% (21 of 30), and 50% (25 of 50), respectively, experienced treatment failure ( , by the x 2 test for trend). Seven (88%) of 8 P ! .001 re-treated children who remained infected at the 8-month follow-up visit lived in a household with at least 7 persons, compared with 23 (55%) of 42 successfully treated children. Similarly, among the 35 children in the intervention group who were H. pylori negative at the 2-month follow-up visit, 4 (66%) of 6 who became reinfected by the 8-month follow-up visit lived in a household with at least 7 persons, compared with 6 (22%) of 27 who remained infection free.
Multivariate analysis of risk factors for treatment failure. Initial multivariate models were constructed by including all variables other than household-crowding measures that were associated with treatment failure at the 90% confidence level during univariate analysis. Backward logistic regression analysis was then performed after removing the variables with a P value of у.05, including male sex (OR, 1.2; ), hemoglobin P p .75 ). Treatment doses, a treatment reg-P p .083 imen that did not include metronidazole, and body mass index remained in the preliminary model.
Three household-crowding measures were associated with infection on univariate analysis. Of these, the number of H. pylori-infected 7-11-year-old children was a complete subset of all 7-11-year-old children, which was a complete subset of all household members. Consequently, these 3 variables were entered independently into the preliminary model, and only total number of household members demonstrated a significant association with treatment failure. In the final model, number of treatment doses consumed, lack of metronidazole use, body mass index, and total number of household members remained significantly associated with treatment failure; adjustment for village of residence did not substantially alter final results (table  4) . The model correctly classified 90% of children with continued infection and 69% of children who did not have infection.
Twenty-two households had 2-3 enrolled children in the intervention group who were evaluated at 2 months. Consequently, values for the number of treatment doses and the total number of household members were not independent for each study subject. Thus, we conducted an additional analysis limited to the 56 children who did not have other enrolled household members plus 1 randomly selected enrolled child from each of the remaining 22 households. Only 5 of these 78 children received metronidazole, and none had infection at 2 months; consequently, a stable model could not be created with this variable. The measures of association did not change substantially according to the number of treatment doses consumed (adjusted OR, 0.88; 95% CI, 0.81-0.96), body mass index (adjusted OR, 0.61; 95% CI, 0.39-0.97), and household population (adjusted OR, 1.4; 95% CI 0.97-1.9). This model NOTE. Data are mean values. The standard regimen included amoxicillin, clarithromycin, and lansoprazole; metronidazole was replaced by amoxicillin for 7 children allergic to penicillin and by clarithromycin for 1 child allergic to macrolides.
a Data refer to children other than the index child who were in the study, lived in the same household as the index child, and also had H. pylori infection. correctly classified 86% of children with continued infection and 61% of children who did not have infection.
DISCUSSION
Among children with a high prevalence of H. pylori infection, we found that poor treatment compliance, household crowding, and lower body mass index were risk factors for treatment failure and that a metronidazole-containing treatment regimen improved the chance of therapeutic success. Previous pediatric treatment trials have had у1 of the following methodological limitations: small sample size, lack of control subjects, and short period of follow-up (4-6 weeks). In addition, most studies have been conducted among European and North American populations with a low prevalence of H. pylori infection [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The current study was relatively robust and may be more applicable to areas of the world with high H. pylori infection prevalences, such as South America [26] [27] [28] , Africa [29] , and Asia [30] , where most of the world's children live. Most previous clarithromycin-and amoxicillin-based pediatric efficacy trials have found higher response rates than ours after a single course of therapy [5, 7, [11] [12] [13] [14] 31] . These studies reported high rates of compliance or no data on compliance [5, 31] . Our study and at least 1 previous, noncontrolled clarithromycin-and amoxicillin-based trial [32] suggest that, when compliance is poor, treatment response rates are low. We found that the risk of treatment failure increased as the number of missed doses increased, with no evidence of a threshold effect. Initial poor compliance was common, despite hiring monitors in each village to observe and document therapy; this may have been exacerbated by concurrent iron administration. Compliance improved somewhat with intensive monitoring that included true, directly observed therapy by nonlocal staff; because of the small sample size, we could not evaluate formally the effect of monitoring on compliance for individual villages. Potential reasons for poor compliance are numerous and include the potential effect of the lack of clinical symptoms.
Previous studies have shown that clarithromycin resistance before treatment initiation predicts failure of clarithromycincontaining regimens [32] [33] [34] . Although we did not determine patterns of antibiotic resistance among H. pylori isolates from our study population, clarithromycin resistance was found among 31% of H. pylori isolates collected from primarily adult Alaska Natives residing in western Alaska (US Centers for Disease Control Arctic Investigations Program, 1999-2003, unpublished data). Thus, the initially low rate of treatment success we observed may have been due, in part, to antibiotic resistance. In contrast to clarithromycin, in vitro metronidazole resistance does not necessarily predict clinical failure of metronidazolecontaining regimens [34] [35] [36] [37] [38] . This may explain why treatment success was much higher when treatment included metronidazole, even after controlling for important confounders and despite 44% metronidazole resistance among isolates from adult Alaska Natives from western Alaska. It may also explain why, after repeat therapy (when metronidazole and bismuth replaced clarithromycin), infection resolution was high regardless of compliance (although this effect could have resulted from a decreased bacterial load after initial therapy) and despite a longer interval between treatment and follow-up examination.
Because Alaska Natives from the western part of the state have a high H. pylori infection prevalence [17, 22] , the substantial initial treatment failure rate and the association between treatment failure and household size in our study and others [39] [40] [41] [42] [43] may reflect the risk of repeated exposure and reinfection. This hypothesis is also consistent with our finding that most children who did not respond to the second round of treatment or who became reinfected between the 2-month and 8-month follow-up visits lived in relatively crowded households. This demonstrates the difficulty in implementing individual treatment strategies among populations residing in H. pylori-endemic regions and, possibly, why few investigators have elected to conduct treatment trials among these cohorts.
Despite these issues, only 17% of children who were uninfected at the 2-month follow-up visit were reinfected at the 8-month follow-up visit, suggesting that reinfection explains a relatively small proportion of treatment failures.
Our study had several limitations. We did not collect isolates or resistance data from our study subjects; consequently, we could not evaluate directly the impact of resistance on treatment failure. The study was conducted among a relatively unique US population, limiting our ability to generalize results to developed country populations. However, results may be applicable to populations in the developing world with similar epidemiological characteristics of H. pylori infection, as well as to other indigenous North American populations [44] . We did not rigorously monitor medicine intake in most instances, making it difficult to fully evaluate fully the effects of poor compliance. Treated children did not have a recognized medical indication for therapy, and the presence of H. pylori-induced pathology may affect treatment response [33] . Children with normal iron levels were not included in the treatment phase, and, thus, results were not necessarily representative of all infected children. Finally, sample size limitations prevented evaluation of some risk factors, such as reasons for not responding to the second treatment course and village-level risk factors.
Alaska Native children aged 7-11 years living in an area with a high prevalence of H. pylori infection were likely to respond successfully to treatment but only when combined with up to 2 rounds of therapy and treatment monitoring to improve compliance. In high-prevalence areas with crowded households, health care professionals should consider retesting children after initial therapy and instituting measures to increase compliance if treatment failure occurs. Further research should evaluate whether including metronidazole in pediatric treatment regimens can decrease the number of doses needed to treat infection and resolve associated disease, even in areas with a relatively high rate of drug resistance among and a high prevalence of infection with H. pylori.
